Atomoxetine and DAW2020 for treating obstructive sleep apnea
Official title: Effect of Atomoxetine and DAW2022 on OSA Severity
Run by Brigham and Women's Hospital · NCT05350215 · Data updated 2026-11-12
This study is testing if a combination of two medications can help people with obstructive sleep apnea breathe better while they sleep.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Ages | 21 Years to 70 Years |
| Sex | All |
| Enrollment | 18 (estimated) |
| Sponsor | Brigham and Women's Hospital Academic / other |
| Locations | 1 site (Boston, Massachusetts) |
| Status | Recruiting |
| Started | June 1, 2022 |
| Main results expected | December 1, 2026 |
| Study ends | December 1, 2026 |
| Registry record updated | July 10, 2026 |
| Trial ID | NCT05350215 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are individuals diagnosed with moderate-to-severe obstructive sleep apnea, characterized by an apnea-hypopnea index (AHI) of 15 events per hour or more.
✕Probably not a fit
Patients with other significant respiratory disorders, major organ system diseases, or those on medications that affect respiration may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the effects of atomoxetine and DAW2020 on the severity of obstructive sleep apnea (OSA). Participants will undergo two overnight sleep studies, one with the drug combination and one with a placebo, to monitor sleep and respiratory variables. The study aims to assess the efficacy of these medications in reducing OSA severity while minimizing side effects associated with previous treatments. A thorough medical history and physical examination will be conducted prior to each study night.
Why it matters
Potential benefit: If successful, this study could provide a new treatment option for patients with moderate-to-severe obstructive sleep apnea.
How similar studies have gone: Previous studies have shown promising effects of atomoxetine and oxybutynin on OSA severity, but this specific combination with DAW2020 is novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Moderate-to-severe OSA (AHI ≥ 15 events/hr) Exclusion Criteria: * All participants will be healthy and without major organ system disease that would preclude undergoing the physiological measurements. * Use of medications expected to stimulate or depress respiration (including opioids, barbiturates, acetazolamide, doxapram, almitrine, theophylline, 4-hydroxybutanoic acid). * Use of SNRIs/SSRIs. * Conditions likely to affect OSA physiology: neuromuscular disease or other major neurological disorder, heart failure (also below), or any other unstable major medical condition. * Sleep disordered breathing or respiratory disorders other than obstructive sleep apnea: * Other sleep disorders: periodic limb movements (periodic limb movement arousal index \> 10/hr), narcolepsy, or parasomnias. * Hypersensitivity to the study drug (angioedema or urticaria) * Contraindications to DAW2020 * Use of medications that lengthen QTc interval * Hypokaliemia, hypomagnesemia, uncontrolled thyroid disease * Severe claustrophobia.
Where it's running
-
Brigham and Women's Hospital
Boston, Massachusetts, United States Recruiting
Study contacts
- Study coordinator: Ludovico Messineo, MD, PhD
- Email: lmessineo@bwh.harvard.edu
- Phone: 18572726188
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Multimodal Deep Learning to Predict Sleep Apnea Severity from SpO2 and Ballistocardiography
Researchers are testing a smart-mattress-based method that uses SpO2 and ballistocardiography data to predict sleep apnea severity in adults undergoing overnight sleep study.
-
Nightly wearable monitoring with at-home submental electrical stimulation for sleep apnea
This pilot test checks whether wearing a ring sensor at night and doing a 4-week at-home submental electrical stimulation is feasible for adults with obstructive sleep apnea and looks at changes in sleep metrics.
-
Functional capacity and muscle function in adults with obstructive sleep apnea
This study tests how obstructive sleep apnea affects respiratory and peripheral muscle strength, endurance, and upper‑extremity function compared with healthy adults.
-
Transcutaneous Electrical Stimulation for Obstructive Sleep Apnea
This study tests whether applying gentle electrical stimulation to the throat muscles at night can reduce sleep apnea severity in adults with obstructive sleep apnea.
-
Physical activity habits and sleep/ breathing in obstructive sleep apnea
This study tests whether daily physical activity habits affect sleep quality and breathing measurements in people with obstructive sleep apnea who are on CPAP therapy.
-
CES-EES score and a wearable ring for diagnosing obstructive sleep apnea
This study tests whether the CES-EES clinical score and the Belun Ring wearable can accurately diagnose obstructive sleep apnea without in-lab polysomnography in adults referred for suspected OSA.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.